Form 4: Rigel Pharmaceuticals CMO Executes Stock Transaction

Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, reported the disposition of 850 shares of common stock.

Summary

• Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, Inc. (RIGL), disposed of 850 shares of common stock on June 1, 2026.
• The transaction was executed at a price of $29.86 per share.
• The disposition was made to satisfy tax withholding obligations related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 34,003 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a change in management sentiment.

Positives

• The transaction was a routine administrative action related to tax obligations rather than a discretionary sale of shares.

Negatives

• The reporting person reduced their total direct equity stake in the company by 850 shares.

Risks

• None identified; this is a standard regulatory disclosure of a non-discretionary tax-related transaction.

Future Outlook

Not applicable; this is a historical disclosure of a past transaction.

Industry Context

StockSavvy.ai notes that tax-withholding transactions are standard practice for corporate executives in the biotechnology sector to cover liabilities arising from the vesting of restricted stock units or other equity-based compensation.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices where shares are withheld by the issuer to satisfy statutory tax requirements.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was non-discretionary and related to tax obligations.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Trading, Biotech, Equity Compensation